Cargando…

Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarcinoma

Background: There is a high prevalence of diabetes mellitus (DM) in patients with pancreatic ductal adenocarcinoma (PDAC). An inflammatory response is considered as a potential mechanism involved in the process. The systemic immune-inflammation (SII) index is an integrated and novel inflammatory ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Guanhua, Tan, Chunlu, Liu, Xubao, Wang, Xing, Tan, Qingquan, Chen, Yonghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917636/ https://www.ncbi.nlm.nih.gov/pubmed/36769405 http://dx.doi.org/10.3390/jcm12030756

Ejemplares similares

Association Between the Neutrophil-To-Lymphocyte Ratio and Diabetes Secondary to Exocrine Pancreatic Disorders
por: Chen, Guanhua, et al.
Publicado: (2022)

Elevated Bile Acid Is Associated with Worsened Impaired Glucose Homeostasis in Pancreatic Ductal Adenocarcinoma Patients with Extrahepatic Cholestasis through Increased Hepatic Insulin Clearance
por: Yang, Jie, et al.
Publicado: (2023)

Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
por: Chen, Guanhua, et al.
Publicado: (2023)

Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis
por: Zheng, Zhenjiang, et al.
Publicado: (2019)

Prevention and Treatment of Grade C Postoperative Pancreatic Fistula
por: Xiang, Chengzhi, et al.
Publicado: (2022)

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study
por: Xiong, Junjie, et al.
Publicado: (2016)

Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer
por: Zheng, Zhenjiang, et al.
Publicado: (2019)

Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus
por: Tang, Zhen-Chu, et al.
Publicado: (2020)

Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck
por: Zheng, Zhenjiang, et al.
Publicado: (2019)

Deleted in liver cancer-1 inhibits cell growth and tumorigenicity in human pancreatic cancer
por: ZHENG, ZHENJIANG, et al.
Publicado: (2013)

Laparoscopic spleen-preserving distal versus central pancreatectomy for tumors in the pancreatic neck and proximal body
por: Zhang, Hao, et al.
Publicado: (2019)

High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma
por: Aziz, Mohammad Hosein, et al.
Publicado: (2022)

Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma
por: Wang, Rui, et al.
Publicado: (2023)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

Early recurrence detected by (18)F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma
por: Wang, Li, et al.
Publicado: (2020)

MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma
por: Wang, Xing, et al.
Publicado: (2020)

Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study
por: Tan, Qingquan, et al.
Publicado: (2022)

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
por: Badowska-Kozakiewicz, Anna, et al.
Publicado: (2022)

GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021)

Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
por: Wang, Ziyao, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis
por: Yang, Bing, et al.
Publicado: (2021)

Proteome alterations in pancreatic ductal adenocarcinoma
por: Pan, Sheng, et al.
Publicado: (2020)

Unusual metastasis of papillary thyroid cancer to the pancreas, liver, and diaphragm: a case report with review of literature
por: Ren, Haoyuan, et al.
Publicado: (2020)

The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in Patients with Pancreatic Ductal Adenocarcinoma
por: Hu, Si-Pin, et al.
Publicado: (2020)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
por: Li, Yan, et al.
Publicado: (2022)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma
por: Wu, Li-Xia, et al.
Publicado: (2019)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
por: Murakami, Shigekazu, et al.
Publicado: (2016)

Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
por: Hilmi, Marc, et al.
Publicado: (2018)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma
por: Jiang, Zhengting, et al.
Publicado: (2022)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n62qe036uiaa722mgojt1hebcr